Results 181 to 190 of about 27,503 (257)

Association between dipeptidyl peptidase-4 inhibitor use and risk of Parkinson's disease among patients with diabetes mellitus: a retrospective cohort study. [PDF]

Aging (Albany NY)
Huang KH, Yang Y, Gau SY, Tsai TH, Lee CY.   +4 more
europepmc   +1 more source

Integrated Transcriptomic and Physiological Analyses Reveal Disruption of Digestive Homeostasis Induced by Protease Inhibitors in Anticarsia gemmatalis Caterpillars

Archives of Insect Biochemistry and Physiology, Volume 123, Issue 2, October 2026.
The peptides SKTI and GORE‐2 triggered distinct midgut responses in Anticarsia gemmatalis (Lepidoptera: Erebidae). SKTI promoted compensatory digestive and antioxidant responses, whereas GORE‐2 caused broader digestive protease repression, weaker antioxidant activation, and greater epithelial damage.
Neilier Rodrigues da Silva Júnior, Eulálio Gutemberg Dias dos Santos, Daniel Guimarães Silva Paulo, Yaremis Meriño‐Cabrera, Ian de Paula Alves Pinto, Maria Julia Summy, Ian Lucas Batista Santos, Milena Godoi Lima, Maria Clara Neves Gomes Rodrigues, Rafael Junior de Andrade, José Eduardo Serrão, Elizabeth Pacheco Batista Fontes, Humberto Josué Oliveira Ramos, Maria Goreti de Almeida Oliveira   +13 more
wiley   +1 more source

Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Kamrul-Hasan ABM, Dutta D, Nagendra L, Sharma M, Patra S, Bhattacharya S.   +5 more
europepmc   +1 more source

Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αVβ3‐Targeted Cancer Therapy

Chemistry – A European Journal, Volume 32, Issue 37, 1 October 2026.
Integrin αVβ3‐targeting small‐molecule drug conjugates (SMDCs) were synthesized by conjugating a cryptophycin payload through a neutrophil elastase‐cleavable NPV‐PABC linker. RGD peptidomimetic and linker epimers served as controls for targeting and enzymatic cleavage, and the resulting conjugates displayed subnanomolar cytotoxicity in vitro.
Dominic Seißenschmidt, Henriette Hartung, Jonah Kammer, Norbert Sewald   +3 more
wiley   +1 more source

Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease. [PDF]

Lab Invest
Al Tuhaifi T, Zhong J, Yang HC, Fogo AB.
europepmc   +1 more source

Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China

Clinical Pharmacology in Drug Development, Volume 15, Issue 10, October 2026.
Abstract This single‐center, single‐arm, Phase I study evaluated drug–drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty‐two subjects sequentially received metformin monotherapy (Days 1–4), cofrogliptin monotherapy (Days 6–34), and combination therapy (Days 38–47).
Cheng Cui, Na Liu, Chang Chu, Shu Niu, Yang Huang, Fangqiong Li, Yaming Li, Haiyan Li, Dongyang Liu   +8 more
wiley   +1 more source

A case of bullous pemphigoid and renal disease after dipeptidyl peptidase 4 inhibitor administration. [PDF]

CEN Case Rep
Suenaga A, Sawa N, Oba Y, Ikuma D, Sekine A, Yamanouchi M, Hasegawa E, Mizuno H, Suwabe T, Hayashi N, Kono K, Kinowaki K, Ohashi K, Miyazono M, Yamaguchi Y, Ubara Y.   +15 more
europepmc   +1 more source

Harnessing Terminalia arjuna in Next Generation Phytomedicine: Cutting Edge Nutraceutical Trends Shaping Food and Health

Food Science &Nutrition, Volume 14, Issue 10, October 2026.
This graphical abstract illustrates the complete translational pipeline of Terminalia arjuna in modern phytomedicine and functional food development. It is rich in key bioactive compounds like arjunolic acid, arjungenin, flavonoids, and tannins which serve as the foundation for the plant's versatile medicinal uses and offers broad therapeutic benefits ...
Ishani Banerjee, Fahika Nazeerulla, Manash Kumar Paul, Sujit Kumar Bhutia, Deblina Basu, Subhadip Mukhopadhyay   +5 more
wiley   +1 more source

Investigation of Glucose Metabolism by Continuous Glucose Monitoring and Validation of Dipeptidyl Peptidase 4 Inhibitor Use in Patients with Myotonic Dystrophy Type 1. [PDF]

J Clin Med
Takada H, Matsumura T, Shimamura H, Matsui M, Kon S, Fukumoto A, Kubota T, Yoshida K, Iwahashi H, Takahashi MP.   +9 more
europepmc   +1 more source

Elevated endogenous glucagon‐like peptide‐1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology

General Psychiatry, Volume 39, Issue 5, October 2026.
ABSTRACT Background Alzheimer's disease (AD), a neurodegenerative disorder, is pathologically defined by the accumulation of amyloid‐β (Aβ) plaques, hyperphosphorylated tau tangles and sustained neuroinflammation. Glucagon‐like peptide‐1 (GLP‐1), originally characterised as an incretin hormone, is also expressed endogenously in the brain.
Jianping Li, Chenhui Ji, Jintao Wang, Jinwen Xiao, Haixia Li, Xinyi Xie, Nan Zhi, Yaying Song, Wenwei Cao, Liling Wang, Jieli Geng, Rujing Ren, Gang Wang   +12 more
wiley   +1 more source